Daiichi axes 170-person Indian R&D site

India flag
The closure follows the shuttering of Daiichi sites in Europe

Daiichi Sankyo is to shutter its 170-person Indian R&D site. The Japanese drugmaker brought the site into its network in 2010 following its $4.6 billion acquisition of Ranbaxy Laboratories, but has now decided it can boost R&D productivity by axing the operation.

Today, a team of 170 people work at the facility on the discovery and preclinical development of small molecules against infectious and autoimmune diseases. Under Ranbaxy the unit chalked up some successes, gaining a reputation for its synthetic chemical research capabilities and becoming the heart of an alliance with GlaxoSmithKline. But Daiichi management has decided to close the unit and transfer pipeline programs in development at the site to its main R&D division.

The decision is part of a broader effort at Daiichi to cut R&D costs and focus remaining resources on areas other than those worked on at the site in Gurgaon, India. That facility joins R&D sites in the United Kingdom and Germany on the list of those axed by Daiichi in the past two years.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

In parallel to the internal cuts, Daiichi has penned a string of oncology deals designed to give it a pipeline of candidates that can increase its success rate in the clinic. The most recent and high profile of these agreements is the deal with Kite Pharma, which gave Daiichi the rights to CAR-T drug KTE-C19 in Japan. KTE-C19 is now spearheading an immuno-oncology pipeline that Daiichi is hoping to flesh out through collaborations with companies including AgonOx and Zymeworks.

The shift toward oncology and increased reliance on external collaborations rendered the Indian site a poor fit for the new look Daiichi. Gurgaon made more sense as a Daiichi outpost in 2010, when the Japanese drugmaker was in the middle of an ultimately doomed attempt to make India a cornerstone of its business. That strategy ended in 2014 when Daiichi cut its losses on its buyout of Ranbaxy.

Read more on

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.